Accessibility Menu

Ceryvyn Therapeutics(OTC) CYVNY

Market Cap$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-99%
5 Year-100%
1 Year-99%
1 Month+5%
$0.02
+0.00%
+0.00Today
Ceryvyn Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.022026-08-26
Ceryvyn Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.45%USD 0.022026-08-17
1 month+5.45%USD 0.022026-07-27
3 month-54.95%USD 0.052026-05-28
Year to date-1.11%USD 0.022025-12-31
1 year-99.32%USD 3.412025-03-17
3 year-99.28%USD 3.232023-08-23
5 year-99.72%USD 8.252021-08-27
Since inception-99.41%USD 3.952012-04-12

Ceryvyn Therapeutics Financials at a Glance

Market Cap

$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$1.14

P/E Ratio

0.02

Dividend

$0.00

Beta (Volatility)

1.71 (High)

Price

$0.02

Volume

2

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.00 - $3.41

Estimated Earnings Date

N/A

CYVNY News

AMD

Why Opthea Stock Skyrocketed Today

Keith SpeightsJun 16, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ceryvyn Therapeutics

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Industry

Biotechnology

Sector

Health Care

CEO

Frédéric Guerard, PharmD

Website

www.opthea.com

CYVNY Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

50.00%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

171.00M

Volume

2

Avg. Volume

25.36K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Ceryvyn Therapeutics Performance Analysis

Ceryvyn Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 90,358N/A
20232023-06-30USD 107,91719.4%
20242024-06-30USD 125,10615.9%
20252025-06-30USD 24,957-80.1%
Ceryvyn Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -1.83N/A
20232023-06-30USD -2.2321.8%
20242024-06-30USD -2.7724.4%
20252025-06-30USD -1.06-61.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,711.76-0.00%
^DJIDJI
$53,559.99-0.00%
^IXICNASDAQ
$26,402.42-0.01%
BTCBitcoin
$78,843.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.82+0.10%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.34-0.10%
IBITiShares Bitcoin Trust
$43.90-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.54+0.02%

Questions About CYVNY

What is the current price of Ceryvyn Therapeutics?

Ceryvyn Therapeutics is trading at $0.02 per share.

What is the 52-week range for Ceryvyn Therapeutics?

Over the past 52 weeks, Ceryvyn Therapeutics has traded between $0.00 and $3.41.

How much debt does Ceryvyn Therapeutics have?

As of the most recent reporting period, Ceryvyn Therapeutics reported total debt of $246.99M.

How much cash does Ceryvyn Therapeutics have on hand?

Ceryvyn Therapeutics reported $48.44M in cash and cash equivalents in its most recent financial results.

What is Ceryvyn Therapeutics’s dividend yield?

Ceryvyn Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services